These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37855394)

  • 1. The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E
    Sun G; Fuller H; Fenton H; Race AD; Downing A; Williams EA; Rees CJ; Brown LC; Loadman PM; Hull MA
    Int J Cancer; 2024 Mar; 154(5):873-885. PubMed ID: 37855394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
    Davies JR; Mell T; Fuller H; Harland M; Saleh RNM; Race AD; Rees CJ; Brown LC; Loadman PM; Downing A; Minihane AM; Williams EA; Hull MA
    Cancer Prev Res (Phila); 2023 Nov; 16(11):621-629. PubMed ID: 37756582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatty acid desaturase insertion-deletion polymorphism rs66698963 predicts colorectal polyp prevention by the n-3 fatty acid eicosapentaenoic acid: a secondary analysis of the seAFOod polyp prevention trial.
    Sun G; Li YN; Davies JR; Block RC; Kothapalli KS; Brenna JT; Hull MA
    Am J Clin Nutr; 2024 Aug; 120(2):360-368. PubMed ID: 38879016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.
    Hull MA; Sandell AC; Montgomery AA; Logan RF; Clifford GM; Rees CJ; Loadman PM; Whitham D
    Trials; 2013 Jul; 14():237. PubMed ID: 23895505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary excretion of thromboxane and prostacyclin metabolites during chronic low-dose aspirin: evidence for an extrarenal origin of urinary thromboxane B2 and 6-keto-prostaglandin F1 alpha in healthy subjects.
    Chiabrando C; Rivoltella L; Martelli L; Valzacchi S; Fanelli R
    Biochim Biophys Acta; 1992 Feb; 1133(3):247-54. PubMed ID: 1737057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
    Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
    Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation.
    Petrucci G; Giaretta A; Ranalli P; Cavalca V; Dragani A; Porro B; Hatem D; Habib A; Tremoli E; Patrono C; Rocca B
    Clin Transl Sci; 2022 Dec; 15(12):2958-2970. PubMed ID: 36200184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial.
    Fuller H; Race AD; Fenton H; Burke L; Downing A; Williams EA; Rees CJ; Brown LC; Loadman PM; Hull MA
    Prostaglandins Leukot Essent Fatty Acids; 2023 May; 192():102570. PubMed ID: 37003144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: Evidence of rebound elevated colorectal polyp risk after short-term aspirin use.
    Downing A; Fenton H; Nickerson C; Loadman PM; Williams EA; Rees CJ; Brown LC; Morris EJA; Hull MA
    Aliment Pharmacol Ther; 2023 Sep; 58(6):562-572. PubMed ID: 37518954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nabumetone on prostanoid biosynthesis in humans.
    Cipollone F; Ganci A; Panara MR; Greco A; Cuccurullo F; Patrono C; Patrignani P
    Clin Pharmacol Ther; 1995 Sep; 58(3):335-41. PubMed ID: 7554708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina.
    Cipollone F; Patrignani P; Greco A; Panara MR; Padovano R; Cuccurullo F; Patrono C; Rebuzzi AG; Liuzzo G; Quaranta G; Maseri A
    Circulation; 1997 Aug; 96(4):1109-16. PubMed ID: 9286937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment.
    Santilli F; Paloscia L; Liani R; Di Nicola M; Di Marco M; Lattanzio S; La Barba S; Pascale S; Mascellanti M; Davì G
    J Am Heart Assoc; 2014 Jul; 3(4):. PubMed ID: 25037196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial.
    Hull MA; Sprange K; Hepburn T; Tan W; Shafayat A; Rees CJ; Clifford G; Logan RF; Loadman PM; Williams EA; Whitham D; Montgomery AA;
    Lancet; 2018 Dec; 392(10164):2583-2594. PubMed ID: 30466866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet activation in patients with colorectal cancer.
    Sciulli MG; Filabozzi P; Tacconelli S; Padovano R; Ricciotti E; Capone ML; Grana M; Carnevale V; Patrignani P
    Prostaglandins Leukot Essent Fatty Acids; 2005 Feb; 72(2):79-83. PubMed ID: 15626589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspirin dosage and thromboxane synthesis in patients with vascular disease.
    Hart RG; Leonard AD; Talbert RL; Pearce LA; Cornell E; Bovill E; Feinberg WM
    Pharmacotherapy; 2003 May; 23(5):579-84. PubMed ID: 12741431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of the thromboxane A2/prostacyclin ratio in the urine of patients with retinal vascular occlusion through the low-dose-aspirin therapy using the gas chromatography/selected ion monitoring method.
    Mizugaki M; Hishinuma T; Matsumura E; Murai Y; Yamazaki T; Yamanobe S; Tamai M
    Prostaglandins Other Lipid Mediat; 1999 Nov; 58(5-6):253-62. PubMed ID: 10593167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary excretion and origin of 11-dehydro-2,3-dinor-thromboxane B2 in man.
    Chiabrando C; Rivoltella L; Alberti E; Bonollo M; Djurup R; Fanelli R
    Prostaglandins; 1993 May; 45(5):401-11. PubMed ID: 8321910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Platelets; 2011; 22(3):188-95. PubMed ID: 21231857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of urinary 11-dehydro-thromboxane B
    Simeone P; Boccatonda A; Liani R; Santilli F
    Ageing Res Rev; 2018 Dec; 48():51-78. PubMed ID: 30273676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.